Centaurus Financial’s Puma Biotechnology PBYI Stock Holding History

Centaurus Financial’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1	Closed	–	–	1588
2018 Q2	$0	Buy	+1	New	+$58	﹤0.01%	2349

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Centaurus Financial's PBYI Position: Q3 2018 in Review

Centaurus Financial sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 1 share.

Centaurus Financial first reported a position in PBYI in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

Centaurus Financial reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 1 Puma Biotechnology share in Q3 2018.
Centaurus Financial first reported a position in Puma Biotechnology in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Puma Biotechnology position peaked at $0 in Q2 2018.
156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.